Strong momentum29 Sep 2022 08:05
Sounds alright:
The strong momentum in the Group seen during the first half of 2022 has continued post-period end. Most notably the Phase I clinical trial evaluating the safety and tolerability of AVA6000 is making excellent progress and is now recruiting patients into the fourth dose escalation cohort, at a dose of 200 mg/m2, equivalent to more than double the normal dose of doxorubicin.
"I believe success in the ongoing Phase Ia study will be a major value inflection point for the Group as, not only is it important for the continued development of AVA6000, but it will also provide validation of the pre|CISION mechanism of action, and therefore the platform as a whole. If then applied more broadly, the validated platform would create a promising pipeline of chemotherapies with the potential to significantly improve patients' lives. It is also exciting to see AVA3996, the next pre|CISION drug candidate, selected for pre-clinical development. We look forward to providing future updates on this."